Home
Investment
News & Views
Company News
news storage
Thursday tips round-up: Thornton's, Lupus Capital, Alliance Pharma
Thu, 09 Feb, 2012
INVESTMENT NEWS
Company Search
Search QCK.COM
Investment Home
News & Views
Top Stories
Charting
Company Search
Watchlist
Market Reports
Market Buzz
Company News
Economic News
New Issues
Other News
Thursday tips round-up: Thornton's, Lupus Capital, Alliance Pharma
Thu, 9 Sep 2010, 05:56:00
Chocolate firm
Thornton
's shares are a perennial underperformer, above £2 in May 2007 but now, at 81½p, lower than they were at the start of 2009. The problem, as was made clear in May's profit warning, is the high street chain. Commercial sales in the first half to the end of June, that is, chocolates that Thorntons make for others, rose by 10 per cent, but in the high street operation, which represents about three fifths of the group, they fell by 3.7 per cent as customers stayed away and the company cut prices. Sell, says the Times. Just as Tomkins, Greg Hutchings' first vehicle, slips slowly into the west after an agreed if controversial takeover bid, his latest,
Lupus Capital
, demonstrates the benefits of life without him. Lupus shares, 17½p at the start of the year, peaked at not far short of £1 in the summer, suggesting that most of the recovery is in there, and sell on more than five times this year's Ebitda. No reason to chase, according to the Times.
Alliance Pharma
, an Alternative Investment Market-listed company, makes its money by buying, marketing and distributing a large range of licensed prescription medicines. And, on the strengthen of yesterday's numbers, the strategy appears to be working. Buy, says the Independent.
SQS
, the German software testing group, posted half-yearly results yesterday, with adjusted pre-tax profits declining to €2.4m, compared to €2.7m last year. On Altium's numbers, SQS trades on a multiple of 9.5 times forecast earnings for this year. That falls to 8 times 2011 earnings. The prospective yield, on the other hand, rises from 3.6 per cent for 2010 to 4.8 per cent by 2012. The Independent says buy. Hotel and coffee shop group
Whitbread
's sales rose 14pc in the first half, and like-for-like revenue increased 7.9pc. That was led by a 10.7pc rise in like-for-likes at Premier Inn and an 8.3pc climb at Costa. The shares are now trading at a price-to-earnings ratio of 14.2 times, and yielding 2.7pc. Morgan Stanley calls them "good value for a business with cyclical upside, strong growth prospects and an attractive market position". Buy, says the Telegraph. Please note: Digital Look provides a round-up of news, tips and information that is impacting share prices and the market. Digital Look cannot take any responsibility for information provided by third parties. This is for your general information only as not intended to be relied upon by users in making an investment decision or any other decision. Please obtain a copy of the relevant publication and carry out your own research before considering acting on any of this information.
Related Newspaper Articles:
Questor :Whitbread
-
Telegraph
Questor :Ashtead
-
Telegraph
Investment Column : Thornton
-
The Independent
Investment Column : Alliance Pharma
-
The Independent
Investment Column : Software Quality Systems
-
The Independent
©2004-2009 QCK.com